Marcaban, Sagia .
HRN: 22-11-34 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/24/2022
CEFUROXIME 1.5GM (VIAL)
10/24/2022
10/26/2022
IV
1.5gm
TID
S/P NSVD, Leukocytosis
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes